Boehringer Ingelheim, a pharmaceutical company, has launched a virtual science program called MEDEX (META Heart Failure Discussion for Experts). The program brings together multidisciplinary healthcare professionals from the Middle East, Turkey and Africa (META) region as well as international speakers to discuss updates on the treatment and management of heart failure .
MEDEX sessions, each lasting over 2 hours, will take place weekly primarily on Fridays starting January 21. The January sessions will focus on defining the global challenge of HF, its burden in the META region and prevention of HF in high-risk groups, and early intervention.
In February, sessions will focus on excellence in diagnosis and optimization of diagnostic means in the META region, guidelines for the management of HF and changes in clinical practice. Participants will also discuss SGLT2 inhibitors and new hope in the treatment and management of HF in a low-resource setting.
Heart failure is the leading cause of hospitalization worldwide, affecting more than 60 million people worldwide. Patients with chronic heart failure may have a reduced (HFrEF) or preserved (HFpEF) ejection fraction. HFrEF occurs when the heart muscle does not contract efficiently and less blood is pumped to the body, often linked to previous cardiac events, coronary artery disease and structural damage to the heart. HFpEF occurs when the heart muscle contracts normally, but the left ventricle does not fill with enough blood, often due to stiffening of the heart muscle.
Speaking about the program, Mohammed Al-Tawil, Regional General Manager and Head of Human Pharmacy at Boehringer Ingelheim for the India, Middle East, Turkey and Africa (IMETA) region at Boehringer Ingelheim, said: “The lack of Heart disease is a life-threatening condition, and the risk of death increases with each hospital admission.1 At Boehringer Ingelheim, we are committed to developing innovative therapies and firmly believe that working with healthcare professionals who share our passion for improving the health and well-being of our patients is crucial to combating the burden of heart failure.